Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Decrease in Short Interest

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,890,000 shares, a decrease of 41.8% from the August 31st total of 3,250,000 shares. Based on an average daily volume of 4,500,000 shares, the short-interest ratio is currently 0.4 days. Approximately 11.3% of the shares of the company are sold short. Approximately 11.3% of the shares of the company are sold short. Based on an average daily volume of 4,500,000 shares, the short-interest ratio is currently 0.4 days.

Telomir Pharmaceuticals Trading Up 1.4%

NASDAQ TELO opened at $1.42 on Tuesday. Telomir Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $7.08. The stock has a market cap of $45.84 million, a price-to-earnings ratio of -2.63 and a beta of -0.60. The company’s 50 day moving average is $1.48 and its two-hundred day moving average is $1.99.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.09). Sell-side analysts forecast that Telomir Pharmaceuticals will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TELO. Bank of America Corp DE grew its holdings in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after buying an additional 10,880 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in Telomir Pharmaceuticals during the 4th quarter valued at approximately $103,000. Bank of New York Mellon Corp grew its holdings in Telomir Pharmaceuticals by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 91,353 shares of the company’s stock valued at $295,000 after buying an additional 19,058 shares in the last quarter. Nuveen LLC purchased a new stake in Telomir Pharmaceuticals during the 1st quarter valued at approximately $81,000. Finally, HighTower Advisors LLC purchased a new stake in Telomir Pharmaceuticals during the 1st quarter valued at approximately $139,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.